
VIR
Vir Biotechnology Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
5.250
Open
5.250
VWAP
--
Vol
6.33K
Mkt Cap
725.75M
Low
5.250
Amount
--
EV/EBITDA(TTM)
--
Total Shares
136.06M
EV
-75.91M
EV/OCF(TTM)
--
P/S(TTM)
34.43
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
2.72M
-11.48%
-0.718
-29.58%
2.72M
+14.37%
-0.709
-54.53%
2.72M
-78%
-0.706
-7.12%
Estimates Revision
The market is revising No Change the revenue expectations for Vir Biotechnology, Inc. (VIR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -14.22%.
Revenue Estimates for FY2025
No Change

0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change

0.00%
In Past 3 Month
Stock Price
Go Down

-14.22%
In Past 3 Month
9 Analyst Rating

221.14% Upside
Wall Street analysts forecast VIR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VIR is 16.86 USD with a low forecast of 12.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
2 Hold
0 Sell
Strong Buy

221.14% Upside
Current: 5.250

Low
12.00
Averages
16.86
High
31.00

221.14% Upside
Current: 5.250

Low
12.00
Averages
16.86
High
31.00
Raymond James
initiated
$12
2025-07-11
Reason
Raymond James
Price Target
$12
2025-07-11
initiated
Reason
Raymond James initiated coverage of Vir Biotechnology with an Outperform rating and $12 price target.
Raymond James
Sean McCutcheon
Outperform
initiated
$12
2025-07-11
Reason
Raymond James
Sean McCutcheon
Price Target
$12
2025-07-11
initiated
Outperform
Reason
Raymond James analyst Sean McCutcheon initiated coverage of Vir Biotechnology with an Outperform rating and $12 price target. Vir's VIR-5500 shows "compelling" early Phase 1 data in heavily treated metastatic castration-resistant prostate cancer patients, and VIR-5500 is well-positioned to capture share in the large and growing mCRPC market, the analyst tells investors in a research note. The firm's constructive view is balanced by competitive headwinds in prostate cancer, as well as the company's high burn rate and need for additional financing to bring VIR-5500 through pivotal studies.
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$110 -> $15
2025-05-20
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$110 -> $15
2025-05-20
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Vir Biotechnology to $15 from $110 and keeps a Buy rating on the shares. The company's updated 24-week off-treatment data from the Phase 2 program did not meet functional cure thresholds that would be needed to support a Phase 3 investment in the absence of a global partner in chronic hepatitis B virus, the analyst tells investors in a research note. The firm believes chronic hepatitis delta virus infection is now Vir's clear lead value driver in hepatitis.
Goldman Sachs
Paul Choi
Strong Buy
Maintains
$28 → $21
2025-04-17
Reason
Goldman Sachs
Paul Choi
Price Target
$28 → $21
2025-04-17
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$110
2025-02-28
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$110
2025-02-28
Reiterates
Strong Buy
Reason
Barclays
Gena Wang
Buy
Maintains
$26 → $31
2025-02-28
Reason
Barclays
Gena Wang
Price Target
$26 → $31
2025-02-28
Maintains
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Vir Biotechnology Inc (VIR.O) is -1.93, compared to its 5-year average forward P/E of -7.13. For a more detailed relative valuation and DCF analysis to assess Vir Biotechnology Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-7.13
Current PE
-1.93
Overvalued PE
9.74
Undervalued PE
-24.00
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-3.40
Current EV/EBITDA
-0.17
Overvalued EV/EBITDA
9.08
Undervalued EV/EBITDA
-15.88
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Overvalued
5Y Average PS
23.20
Current PS
70.91
Overvalued PS
40.49
Undervalued PS
5.92
Financials
Annual
Quarterly
FY2025Q1
YoY :
-94.62%
3.03M
Total Revenue
FY2025Q1
YoY :
+74.17%
-139.56M
Operating Profit
FY2025Q1
YoY :
+85.31%
-120.97M
Net Income after Tax
FY2025Q1
YoY :
+83.33%
-0.88
EPS - Diluted
FY2025Q1
YoY :
-28.33%
-79.75M
Free Cash Flow
FY2025Q1
YoY :
+0.10%
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
+106.78%
-2.02K
FCF Margin - %
FY2025Q1
YoY :
+3345.56%
-3.99K
Net Margin - %
FY2025Q1
N/A
ROIC
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 946.49% over the last month.
Sold
0-3
Months
185.2K
USD
4
3-6
Months
474.2K
USD
1
6-9
Months
848.7K
USD
13
0-12
Months
95.0K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 3690.48% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
573.1K
Volume
2
6-9
Months
15.1K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
2
1.1M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 946.49% over the last month.
Sold
0-3
Months
185.2K
USD
4
3-6
Months
474.2K
USD
1
6-9
Months
848.7K
USD
13
0-12
Months
95.0K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
VIR News & Events
Events Timeline
2025-07-24 (ET)
2025-07-24
08:26:24
Vir Biotechnology doses first patient in VIR-5525 trial

2025-05-09 (ET)
2025-05-09
06:07:50
Vir Biotechnology reports data from MARCH Phase 2 clinical study

2025-05-07 (ET)
2025-05-07
17:04:26
Vir Biotechnology reports Q1 EPS (88c), consensus (84c)

Sign Up For More Events
Sign Up For More Events
News
9.0
07-24NewsfilterVir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors
2.0
07-10NASDAQ.COM$VIR stock is up 13% today. Here's what we see in our data.
1.0
05-20NewsfilterVir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit
Sign Up For More News
People Also Watch

WINA
Winmark Corp
375.260
USD
0.00%

VTLE
Vital Energy Inc
20.330
USD
-0.29%

HLX
Helix Energy Solutions Group Inc
6.420
USD
+0.31%

AFYA
Afya Ltd
14.200
USD
+0.14%

DCOM
Dime Community Bancshares Inc
28.650
USD
0.00%

LBRDA
Liberty Broadband Corp
63.580
USD
0.00%

FSCO
FS Credit Opportunities Corp
7.370
USD
+0.27%

SDGR
Schrodinger Inc
21.340
USD
+0.80%

EVEX
Eve Holding Inc
6.600
USD
+0.46%

KLG
WK Kellogg Co
23.070
USD
+0.09%
FAQ

What is Vir Biotechnology Inc (VIR) stock price today?
The current price of VIR is 5.25 USD — it has increased 0 % in the last trading day.

What is Vir Biotechnology Inc (VIR)'s business?

What is the price predicton of VIR Stock?

What is Vir Biotechnology Inc (VIR)'s revenue for the last quarter?

What is Vir Biotechnology Inc (VIR)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Vir Biotechnology Inc (VIR)'s fundamentals?

How many employees does Vir Biotechnology Inc (VIR). have?
